Trial Profile

Phase 1B Study for PAX-101 in Patients with Long COVID-19 Syndrome

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 17 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Suramin sodium (Primary)
Indications Post acute COVID 19 syndrome
Focus Adverse reactions; Therapeutic Use
Sponsors PaxMedica

Most Recent Events

17 Jan 2022 New trial record
07 Jan 2022 According to a PaxMedica media release, it has received approval from the South African Health Products Regulatory Agency (SAHPRA) for its clinical trial application.The study is expected to start enrolling patients in the first quarter of this year after obtaining South African National Ethics Committee approval.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com